Exploration of the barriers and enablers of benzodiazepines deprescribing in prisons: A qualitative study among health and social care professionals.
Basic Clin Pharmacol Toxicol
; 134(1): 28-38, 2024 Jan.
Article
en En
| MEDLINE
| ID: mdl-37276582
ABSTRACT
BACKGROUND:
The prison environment is a place of high consumption of benzodiazepines (BZDs) due to the anxiety and sleep disturbances, mental disorders, detoxification and trafficking.OBJECTIVE:
The study aims to explore experiences of health and social care professionals on the use of BZDs in prisons, as well as the barriers and enablers to their deprescribing.METHOD:
Semistructured individual interviews with professionals working in a prison setting were performed between March and April 2022, based on an interview guide. They were recorded and transcribed using the NVivo software. A qualitative analysis using an inductive approach based on a thematic analysis was performed.RESULTS:
Sixteen health professionals were interviewed, including psychiatrists, general practitioners, nurses, pharmacists, psychologists, musicologists and pharmacy technicians. The identified barriers to deprescribing BZDs were problems of coordination between prescribers, lack of time and alternatives. Concerning the enablers, therapeutic education groups, staff's awareness of the irrelevance of some medication and multi-professional advice were identified.DISCUSSION:
This study highlights the similarities in deprescribing difficulties between prison and other settings. Some of the levers identified in our study have shown their effectiveness in different settings.CONCLUSION:
Deprescribing is done most of the time in good conditions but requires an additional delay compared to the outside environment.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Médicos Generales
/
Deprescripciones
Tipo de estudio:
Qualitative_research
Límite:
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article